Felix Blei holds a Ph.D. in microbiology and is an expert in natural products, especially alkaloids. He was able to elucidate the biosynthesis of psilocybin, which made significant advancements in understanding the composition, pathways, and enzymatic processes within psychedelic mushrooms. These laid the foundation for his in-vitro biocatalytic route of psilocybin. His discovery of the co-occurrence of beta-carbolines in Psilocybe raises the question of an entourage effect.

Following his Ph.D., he developed the first quantitative rapid tests (QTests) for psilocybin. He expanded the QTest-system for drugs like LSD, MDMA, and more at a project funded by the Federal Ministry of Germany. He founded miraculix, a spin-off from the university, which researches further test procedures and makes the test kits available to users. In cooperation with the addiction aid in Thuringia, he leads the substance analysis in the first mobile drug-checking model project ALIVE